Semaglutide boosts walking ability in diabetes patients with peripheral artery disease ...
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
STAT6 天
Novo Nordisk follows Eli Lilly with its own ‘triple-G’ drug
Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.
AlphaGalileo2 天
Oral Semaglutide Reduces Cardiovascular Events by 14% at Four Years
People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to ...
AZ Animals (US) on MSN2 个月
Check Out the Venomous Defense Mechanism of the Male Platypus
One hormone found in platypus venom, glucagon-like peptide-1 (GLP-1), plays a role in increasing insulin and regulating blood ...
BioSpace13 天
OPKO and Entera Link Up to Advance First Oral GLP-1/Glucagon Drug Into Clinic
Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.
AZoRobotics on MSN12 天
Forget Ozempic—This AI-Found Peptide May Be the Future of Weight Loss
The identification of BRP, an anti-obesity peptide, showcases the transformative role of AI in drug discovery and its ...
Nasdaq13 天
OPKO & Entera Bio To Develop First Oral GLP-1/Glucagon Dual Agonist
(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic ...